HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer In Vitro.

Abstract
We previously reported that brain-derived neurotrophic factor (BDNF)/neurotrophic receptor tyrosine kinase 2 (NTRK2/TRKB) signaling contributes to induction of malignant phenotype of gallbladder cancer (GBC). Recently, pan-TRK inhibitors have been evaluated and their dramatic clinical activity is being shown for a variety of cancer types harboring an NTRK rearrangement in phase I trials. ONO-7579 is an oral pan-TRK inhibitor currently under investigation in phase I/II clinical trial for TRK-rearranged solid tumors. In this study, we evaluated the anticancer effect of ONO-7579 using GBC cells with or without KRAS mutant, NOZ, TYGBK-1. Our study showed that ONO-7579 had a suppressive effect on GBC proliferation in TYGBK-1, and on invasive potential and vascular endothelial growth factor expression in TYGBK-1 and NOZ. Our data indicated that ONO-7579 could be a promising treatment option for patients with GBC.
AuthorsMakoto Kawamoto, Keigo Ozono, Yasuhiro Oyama, Akio Yamasaki, Yoshinao Oda, Hideya Onishi
JournalAnticancer research (Anticancer Res) Vol. 38 Issue 4 Pg. 1979-1986 (04 2018) ISSN: 1791-7530 [Electronic] Greece
PMID29599313 (Publication Type: Journal Article)
CopyrightCopyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Chemical References
  • Brain-Derived Neurotrophic Factor
  • Membrane Glycoproteins
  • ONO-7579
  • Organic Chemicals
  • Protein Kinase Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • BDNF protein, human
  • Receptor, trkB
  • tropomyosin-related kinase-B, human
Topics
  • Brain-Derived Neurotrophic Factor (antagonists & inhibitors)
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Epithelial-Mesenchymal Transition (drug effects)
  • Gallbladder Neoplasms (drug therapy, enzymology, metabolism, pathology)
  • Humans
  • Membrane Glycoproteins (antagonists & inhibitors, biosynthesis)
  • Neoplasm Invasiveness
  • Organic Chemicals (chemistry, pharmacology)
  • Protein Kinase Inhibitors (pharmacology)
  • Receptor, trkB (antagonists & inhibitors, biosynthesis)
  • Vascular Endothelial Growth Factor A (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: